brown kidney decorPhoto by Robina Weermeijer

May 25 2024 10:15:48 — Novartis’ Phase III ALIGN study shows atrasentan significantly reduces proteinuria by 36.1% in IgA nephropathy (IgAN) patients, supporting kidney function preservation. Atrasentan, a selective ETA receptor antagonist, could become a key treatment. IgAN is a progressive kidney disease needing targeted therapies.

The study’s interim results, presented at the ERA Congress, indicate a favorable safety profile. Final results expected in 2026. Novartis aims to address diverse patient needs with its IgAN portfolio, including additional therapies like Fabhalta and zigakibart. FDA submission for atrasentan is planned for early 2024.

By Lisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *

GDPR Cookie Consent with Real Cookie Banner